SLXNHealthcare · Biotechnology

SLXN Stock Forecast: Silexion Therapeutics Corp. Price Predictions for 2026-2027

Last close, 12 Oct 2026

$0.18

The 2 Wall Street analysts covering Silexion Therapeutics Corp. hold a median 12-month price target of $5 — +2705.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 57 of 100 as at 12 Oct 2026 — in the upper half.

Market cap

$3.1M

Ticker Nerd rank

57 / 100

Median analyst target

$5.00

Analysts covering

Revenue$0.0

Operating income−$3.7M

Net income−$3.6M

Free cash flow−$2.9M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Ticker Nerd rank

SLXN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Silexion Therapeutics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Oct 2026

57 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Revisions

Growth

Issuance

Volatility

Momentum

Value

Quality

Size (98): Smaller than most of the companies we track.

Quality (13): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SLXN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SLXN, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says2 analysts

1 Buy1 Hold0 Sell

Low $5.00Median $5.00High $5.00

The green dot is the last close — the median target sits +2705.8% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
15 Dec 2025	Litchfield Hills	Initiates	Buy	$6.00
20 Mar 2025	Maxim Group	Maintains	Buy	—
1 Nov 2024	Maxim Group	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SLXN appears on the weeks it earns a place.

Estimates

SLXN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Silexion Therapeutics Corp. (SLXN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 0.0×
Price / sales: —
Price / book: 26.8×
EV / EBITDA: −0.0×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −457.6%
Return on assets: −165.1%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Silexion Therapeutics Corp. (SLXN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Silexion Therapeutics Corp. has a market value of $3.1M and an enterprise value of $374K.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$14.0M.
Free cash flow in the twelve months to 30 June 2026: −$12.4M.
Shares outstanding: 1.2M.
Trailing P/E: 0.0×; forward P/E: −0.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Silexion Therapeutics Corp. employs 13 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Oct 2026

Data provided by Twelve Data

Peers

SLXN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
SLXNSilexion Therapeutics Corp.	$3.1M	57
VRAXVirax Biolabs Group Ltd.	$2.5M	16
MTNBMatinas BioPharma Holdings, Inc.	$2.7M	45
ELABPMGC Holdings, Inc.	$2.5M	3
BRTXBioRestorative Therapies, Inc.	$2.4M	7
SILOSilo Pharma, Inc.	$2.4M	22
KAPAKairos Pharma Ltd.	$2.8M	39

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Silexion Therapeutics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SLXN news & analysis

Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

GlobeNewsWire · 30 Sept 2026positive

Silexion Therapeutics announced that the first patient has been successfully dosed in its global Phase 2/3 clinical trial of SIL204, which evaluates the drug in combination with standard chemotherapy in patients with locally advanced pancreatic cancer.

Why it matters — Dosing the first patient marks a key milestone in advancing SIL204 through clinical development for locally advanced pancreatic cancer, a significant step for Silexion's pipeline.

Silexion Therapeutics Announces Exercise of Warrants

GlobeNewsWire · 29 Sept 2026positive

Silexion Therapeutics entered definitive agreements for the immediate exercise of outstanding series E warrants to purchase up to 3,216,928 ordinary shares at a reduced exercise price of $0.2603 per share, with expected gross proceeds of $837,366.36. The offering is expected to close on or about September 29, 2026, and proceeds will be used as working capital for general corporate purposes.

Why it matters — The warrant exercise provides the company with additional working capital that could support its ongoing clinical-stage development of RNAi therapies for KRAS-driven cancers.

Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers

GlobeNewsWire · 28 Sept 2026positive

Silexion Therapeutics reported positive preclinical findings for SIL204, showing the drug candidate leverages native serum lipids for intracellular delivery and achieves robust knockdown of the KRAS oncogene in KRAS-driven cancers. The translational research highlights a key mechanism supporting endogenous systemic uptake.

Why it matters — SLXN watchers would care because positive preclinical evidence of SIL204's delivery mechanism and KRAS oncogene knockdown advances the candidate's development in a genetically defined cancer population.

Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences

GlobeNewsWire · 9 Sept 2026neutral

Silexion Therapeutics announced that its management team, including Chief Scientific and Development Officer Dr. Mitchell Shirvan, will present at two industry conferences in Boston in September 2026: the Oncology & Immunology Innovation Partnering & Licensing Summit on September 9 and the 8th Annual RAS-Targeted Drug Development Summit on September 10.

Why it matters — For SLXN watchers, these conference presentations provide the company with opportunities to present its RNAi platform for KRAS-driven cancers to potential partners and investors.

Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 14 Aug 2026positive

Silexion Therapeutics reported its second quarter 2026 financial results and provided a business update. The company advanced its lead candidate SIL204 into an active Phase 2/3 clinical program for locally advanced pancreatic cancer, initiating the trial at Tel Aviv Sourasky Medical Center in July 2026 after receiving clinical trial authorizations from regulators in Israel and Germany.

Why it matters — This update signals a key clinical milestone for SLXN, as SIL204 has moved from regulatory preparation into an active patient-enrolling Phase 2/3 trial with regulatory approvals secured in two jurisdictions.

FAQ

Frequently asked questions about SLXN stock

What is the SLXN stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Silexion Therapeutics Corp. have a median 12-month price target of $5, with estimates ranging from $5 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SLXN stock a buy right now?

Of the 2 analysts covering Silexion Therapeutics Corp., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Silexion Therapeutics Corp. 57 out of 100 across roughly 4,600 US stocks as at 12 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SLXN?

As at 12 Oct 2026, Silexion Therapeutics Corp. ranks 57 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

Will SLXN stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +2705.8% from the last close, and Ticker Nerd's factor model ranks Silexion Therapeutics Corp. 57 out of 100 as at 12 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SLXN stock forecast for 2030?

No analyst covering Silexion Therapeutics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SLXN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $5 over the next 12 months.

What does Silexion Therapeutics Corp. do?

Silexion Therapeutics Corp. is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies for KRAS-driven cancers.

What is the latest news on SLXN?

The most recent item we track (GlobeNewsWire, 30 Sept 2026): "Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer". Silexion Therapeutics announced that the first patient has been successfully dosed in its global Phase 2/3 clinical trial of SIL204, which evaluates the drug in combination with standard chemotherapy in patients with locally advanced pancreatic cancer.

Company

About Silexion Therapeutics Corp.

Silexion Therapeutics Corp. is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies for KRAS-driven cancers. The company’s current work centers on treating difficult solid tumors, with an emphasis on pancreatic cancer and other malignancies linked to KRAS mutations. Its pipeline includes SIL204, a lead siRNA-based candidate designed to silence mutant KRAS using both local and systemic delivery approaches, as well as additional product programs under its LODER delivery platform. Silexion Therapeutics Corp. operates as an oncology-focused developer of targeted genetic therapies, combining drug design and delivery technology to address areas of unmet medical need in cancer treatment.

CEO Mr. Ilan Hadar M.B.A. · 13 employees · Israel · https://silexion.com